McKesson/$MCK
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About McKesson
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Ticker
$MCK
Sector
Primary listing
NYSE
Industry
Health Care Providers & Services
Headquarters
Employees
44,000
ISIN
US58155Q1031
Website
McKesson Metrics
BasicAdvanced
$90B
28.03
$25.72
0.52
$2.75
0.39%
Price and volume
Market cap
$90B
Beta
0.52
52-week high
$733.10
52-week low
$464.42
Average daily volume
873K
Dividend rate
$2.75
Financial strength
Current ratio
0.899
Quick ratio
0.509
Long term debt to equity
-350.708
Total debt to equity
-436.246
Dividend payout ratio (TTM)
10.47%
Interest coverage (TTM)
19.51%
Profitability
EBITDA (TTM)
5,416
Gross margin (TTM)
3.57%
Net profit margin (TTM)
0.92%
Operating margin (TTM)
1.37%
Effective tax rate (TTM)
20.14%
Revenue per employee (TTM)
$8,160,000
Management effectiveness
Return on assets (TTM)
4.31%
Return on equity (TTM)
-211.42%
Valuation
Price to earnings (TTM)
28.026
Price to revenue (TTM)
0.256
Price to book
-43.44
Price to tangible book (TTM)
-6.64
Price to free cash flow (TTM)
17.572
Free cash flow yield (TTM)
5.69%
Free cash flow per share (TTM)
4,102.04%
Dividend yield (TTM)
0.38%
Forward dividend yield
0.39%
Growth
Revenue change (TTM)
16.22%
Earnings per share change (TTM)
14.87%
3-year revenue growth (CAGR)
10.80%
10-year revenue growth (CAGR)
7.21%
3-year earnings per share growth (CAGR)
52.67%
10-year earnings per share growth (CAGR)
15.16%
3-year dividend per share growth (CAGR)
14.54%
10-year dividend per share growth (CAGR)
11.10%
What the Analysts think about McKesson
Analyst ratings (Buy, Hold, Sell) for McKesson stock.
Bulls say / Bears say
McKesson raised its annual profit forecast, driven by strong demand for specialty medicines, indicating robust growth in high-margin segments. (Reuters)
The company completed the divestiture of its Canada-based Rexall and Well.ca businesses, allowing it to focus on expanding its oncology and biopharma growth platforms. (StockTitan)
Analysts have raised McKesson's price targets, with Bank of America increasing it to $755, reflecting confidence in the company's growth trajectory. (Techdows News)
McKesson forecasted second-quarter profit below Wall Street estimates, leading to a 9% drop in shares, indicating potential challenges in meeting earnings expectations. (TradingView News)
The company reported negative free cash flow of $1.5 billion in Q3 2024, partly due to onboarding new customers, which may raise concerns about cash management. (Panabee)
McKesson's Medical-Surgical segment experienced a 15% decline in adjusted operating profit, attributed to lower volumes and shifts in customer/product mix, potentially impacting overall profitability. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.
McKesson Financial Performance
Revenues and expenses
McKesson Earnings Performance
Company profitability
McKesson News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for McKesson stock?
McKesson (MCK) has a market cap of $90B as of June 25, 2025.
What is the P/E ratio for McKesson stock?
The price to earnings (P/E) ratio for McKesson (MCK) stock is 28.03 as of June 25, 2025.
Does McKesson stock pay dividends?
Yes, the McKesson (MCK) stock pays dividends to shareholders. As of June 25, 2025, the dividend rate is $2.75 and the yield is 0.39%. McKesson has a payout ratio of 10.47% on a trailing twelve-month basis.
When is the next McKesson dividend payment date?
The next McKesson (MCK) dividend payment date is unconfirmed.
What is the beta indicator for McKesson?
McKesson (MCK) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.